Rapport Therapeutics, Inc. Common Stock RAPP · Stock Open Rapport Therapeutics, Inc. Common Stock in new tab
Analyst price targets
Recent rating changes, newest first
Rapport Therapeutics, Inc. Common Stock Analysis (RAPP)
Is Rapport Therapeutics, Inc. Common Stock a good investment? Rapport Therapeutics, Inc. Common Stock (RAPP) is currently trading at 25.93 USD. Market analysts have a consensus price target of 62.71 USD. This suggests a potential upside from current levels.
Earnings Schedule: Rapport Therapeutics, Inc. Common Stock is expected to release its next earnings report on Nov. 5, 2026. The market consensus estimate for Forward EPS is -5.11.
Investor FAQ
Does Rapport Therapeutics, Inc. Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is Rapport Therapeutics, Inc. Common Stock?
Rapport Therapeutics, Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 5, 2026. The company currently has a trailing EPS of -3.03.
Company Profile
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. It also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the treatment of hearing/vestibular disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.
Community Discussion